Literature DB >> 15082596

Long term prognosis of fatty liver: risk of chronic liver disease and death.

S Dam-Larsen1, M Franzmann, I B Andersen, P Christoffersen, L B Jensen, T I A Sørensen, U Becker, F Bendtsen.   

Abstract

BACKGROUND AND AIMS: Fatty liver is a common histological finding in human liver biopsy specimens. It affects 10-24% of the general population and is believed to be a marker of risk of later chronic liver disease. The present study examined the risk of development of cirrhotic liver disease and the risk of death in a cohort diagnosed with pure fatty liver without inflammation.
METHODS: A total of 215 patients who had a liver biopsy performed during the period 1976-1987 were included in the study. The population consisted of 109 non-alcoholic and 106 alcoholic fatty liver patients. Median follow up time was 16.7 (0.2-21.9) years in the non-alcoholic and 9.2 (0.6-23.1) years in the alcoholic group. Systematic data collection was carried out by review of all medical records. All members of the study cohort were linked through their unique personal identification number to the National Registry of Patients and the nationwide Registry of Causes of Death, and all admissions, discharge diagnoses, and causes of death were obtained.
RESULTS: In the non-alcoholic fatty liver group, one patient developed cirrhosis during the follow up period compared with 22 patients in the alcoholic group. Survival estimates were significantly (p<0.01) different between the two groups, for men as well as for women, with a higher death rate in the alcoholic fatty liver group. Survival estimates in the non-alcoholic fatty liver group were not different from the Danish population.
CONCLUSIONS: This study revealed that patients with type 1 non-alcoholic fatty liver disease have a benign clinical course without excess mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082596      PMCID: PMC1774026          DOI: 10.1136/gut.2003.019984

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

Review 1.  [Data validity and coverage in the Danish National Health Registry. A literature review].

Authors:  T N Nickelsen
Journal:  Ugeskr Laeger       Date:  2001-12-31

Review 2.  NASH: from liver diseases to metabolic disorders and back to clinical hepatology.

Authors:  Giulio Marchesini; Gabriele Forlani
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

3.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

4.  The pathology of hepatitis C.

Authors:  P J Scheuer; P Ashrafzadeh; S Sherlock; D Brown; G M Dusheiko
Journal:  Hepatology       Date:  1992-04       Impact factor: 17.425

5.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

6.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

Review 7.  Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?

Authors:  A Lonardo
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

8.  Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.

Authors:  M Charlton; P Kasparova; S Weston; K Lindor; Y Maor-Kendler; R H Wiesner; C B Rosen; K P Batts
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

9.  A prospective study of alcoholic liver disease and mortality.

Authors:  I A Bouchier; W S Hislop; R J Prescott
Journal:  J Hepatol       Date:  1992-11       Impact factor: 25.083

10.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  124 in total

1.  Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record.

Authors:  Kathleen E Corey; Uri Kartoun; Hui Zheng; Stanley Y Shaw
Journal:  Dig Dis Sci       Date:  2015-11-04       Impact factor: 3.199

2.  Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.

Authors:  Saleh Daher; Namma Lev Cohen; Muhammad Massarwa; Mahmud Mahamid; Mira Nasser; Wadi Hazou; Rani Oren; Rifaat Safadi; Tawfik Khoury
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

3.  Clinical-pathological conference series from the Medical University of Graz : case no. 131: elevated transaminases in a 30-year-old male.

Authors:  Csilla Putz-Bankuti; Christian Datz; Winfried März; Carolin Lackner; Rudolf E Stauber; Michael Trauner; Hermann Toplak; Tatjana Stojakovic; Guenter J Krejs
Journal:  Wien Klin Wochenschr       Date:  2006-12       Impact factor: 1.704

Review 4.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

5.  β-Adrenergic induction of lipolysis in hepatocytes is inhibited by ethanol exposure.

Authors:  Micah B Schott; Karuna Rasineni; Shaun G Weller; Ryan J Schulze; Arthur C Sletten; Carol A Casey; Mark A McNiven
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

Review 6.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

Review 8.  Drug-induced steatohepatitis.

Authors:  Vaishali Patel; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

9.  Non-invasive means of measuring hepatic fat content.

Authors:  Sanjeev-R Mehta; E-Louise Thomas; Jimmy-D Bell; Desmond-G Johnston; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

10.  The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity.

Authors:  Jun-ichi Takino; Yuka Kobayashi; Masayoshi Takeuchi
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.